Cabaletta Bio Appoints Biopharmaceutical Leader Scott Brun, M.D. to Board of Directors
His expertise will be particularly valuable to Cabaletta as we advance our lead program, DSG3-CAART, in mucosal pemphigus vulgaris, said Steven Nichtberger, M.D., Chief Executive Officer and Co-founder of Cabaletta.
- His expertise will be particularly valuable to Cabaletta as we advance our lead program, DSG3-CAART, in mucosal pemphigus vulgaris, said Steven Nichtberger, M.D., Chief Executive Officer and Co-founder of Cabaletta.
- We welcome him to the Board of Directors and look forward to his contributions to our strategic and operational objectives as we seek to increase shareholder value.
- Earlier in his career, he held positions of increasing leadership responsibility in drug development within the R&D organization at Abbott Laboratories.
- Dr. Brun will succeed Brian Daniels, M.D., who resigned from the Board of Directors effective June 24, 2021, and subsequently joined the Scientific Advisory Board.